CG Oncology said its oncolytic immunotherapy cretostimogene met expectations in a Phase 3 study in intermediate-risk non-muscle invasive bladder cancer, reporting a 68% reduction in the risk of tumor recurrence versus current practice. The therapy is administered intravesically and is designed to target bladder tumor cells harboring a specific mutation, aiming to reduce recurrence while preserving the option for repeat procedures if disease returns. The randomized Phase 3 trial enrolled 367 patients and followed them with scheduled monitoring every three months. The company’s results may influence how clinicians weigh bladder-sparing immunotherapy against the clinical burden of repeated resections over time. Key questions now include whether the recurrence benefit translates into improved progression endpoints and how safety and tolerability profile compares with existing intravesical approaches as regulatory discussions develop.
Get the Daily Brief